Cerebrolysin
Also known as: Cerebrolysin®, FPF-1070
3 notable studies · 3 references
TLDR
Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides studied extensively for stroke recovery, traumatic brain injury, dementia, and neuroplasticity, with considerably more human clinical research than most research-market neuropeptides but mixed trial and systematic-review results that leave its overall clinical benefit uncertain.
Research Supports
- Studied for effects on ischemic stroke recovery and motor rehabilitation
- Investigated for effects on traumatic brain injury recovery
- Examined in Alzheimer's disease and vascular dementia for cognitive and clinical outcomes
- Studied for effects on neuroplasticity, neurogenesis, and neurotrophic signaling
Observations Reported in Research
- Associated with greater improvement in upper-extremity motor function on the Action Research Arm Test in the CARS stroke-rehabilitation trial (Muresanu et al., 2016)
- A meta-analysis of nine randomized trials reported favorable neurological/functional signals, particularly in more severely affected stroke patients (Bornstein et al., 2018)
- A Cochrane review did not find convincing evidence of reduced mortality or clear overall clinical benefit after ischemic stroke
- Trial and systematic-review results across stroke, TBI, Alzheimer's, and vascular dementia remain mixed rather than consistently positive
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Porcine brain-derived peptide preparation; low-molecular-weight peptide mixture; neurotrophic drug preparation
Cerebrolysin is different from almost everything we've covered. It isn't one peptide with one defined amino-acid sequence. It's a standardized mixture of low-molecular-weight peptides and amino acids derived from porcine brain proteins. Research has investigated Cerebrolysin in: - Ischemic stroke - Traumatic brain injury - Alzheimer's disease - Vascular dementia - Cognitive impairment - Neuroprotection - Neuroplasticity - Recovery after neurological injury Cerebrolysin has been used clinically in numerous countries, but it is not FDA-approved in the United States. Unlike many research-market compounds, it also has a surprisingly substantial human clinical literature. The problem is that the results are mixed. That's what makes it a great Aminodex profile.
What Is Cerebrolysin?
Cerebrolysin is produced through controlled enzymatic breakdown of porcine brain proteins. The resulting preparation contains short peptides and free amino acids, rather than a single purified peptide. It has been developed around the idea that small peptide components can produce neurotrophic and neuroprotective effects resembling aspects of endogenous growth-factor signaling. Because it's a mixture, though, its pharmacology is inherently more complicated than something like Semax or Selank. There isn't one Cerebrolysin sequence. There isn't one Cerebrolysin receptor. And the preparation should not simply be described as “BDNF in a vial.”
What Are Researchers Studying?
Ischemic stroke
Stroke is probably Cerebrolysin's best-known research area. Numerous randomized studies have investigated adding Cerebrolysin to standard rehabilitation after ischemic stroke. Some trials report improvements in neurological scores, motor recovery, and functional outcomes. But systematic reviews have been much less enthusiastic. Cochrane analyses have concluded that evidence does not clearly demonstrate reduced mortality or serious adverse outcomes, and the certainty of evidence for several outcomes has been limited. Cerebrolysin has substantial stroke research, but clinical benefit remains debated.
Motor recovery after stroke
One of the most interesting trials is the CARS study, which combined Cerebrolysin with standardized rehabilitation during early stroke recovery. The study reported greater improvement in upper-limb motor function with Cerebrolysin than placebo. That generated considerable interest in whether Cerebrolysin might enhance neuroplasticity during rehabilitation, rather than simply acting as an acute neuroprotectant. Follow-up and replication studies have continued investigating this idea.
Traumatic brain injury
Cerebrolysin has also been investigated following traumatic brain injury. Researchers have studied outcomes involving consciousness, functional recovery, cognition, and neurobehavioral function. Results have been encouraging in some studies but heterogeneous overall. Differences in injury severity, timing, rehabilitation, outcome measures, and study quality complicate interpretation.
Alzheimer's disease
Cerebrolysin has been studied in mild-to-moderate Alzheimer's disease. Trials have reported improvements in certain cognitive measures, global clinical assessments, and behavioral outcomes. But the literature does not establish Cerebrolysin as a disease-modifying Alzheimer's therapy. Evidence is considerably less definitive than for approved modern anti-amyloid treatments regarding their specific biological target, although those therapies have their own limitations.
Vascular dementia
Because Cerebrolysin research spans both neurodegeneration and vascular brain injury, investigators have also studied it in vascular dementia. Some trials and meta-analyses have reported improvements in cognitive or global clinical measures. However, study quality and geographic concentration remain concerns.
Neuroplasticity
One of the more compelling hypotheses is that Cerebrolysin may support neural repair rather than simply preventing immediate neuronal death. Preclinical experiments suggest effects involving neurogenesis, synaptic plasticity, neuronal survival, dendritic remodeling, and neurotrophic signaling. This may help explain why some studies focus on pairing treatment with active rehabilitation.
Neurotrophic signaling
Cerebrolysin is frequently described as having neurotrophic-like activity. Experimental work suggests modulation of pathways associated with BDNF, NGF, synaptic signaling, cell survival, and neurogenesis. But because Cerebrolysin is a complex mixture, describing it as a single growth-factor agonist would be inaccurate.
How Does It Work?
No single mechanism fully explains Cerebrolysin. Proposed mechanisms include: Neuroprotection Reducing neuronal vulnerability during metabolic or ischemic stress. Neuroplasticity Supporting synaptic remodeling and adaptive neural changes. Neurogenesis Experimental studies suggest effects on neural progenitor cells. Neurotrophic signaling Cerebrolysin may influence pathways associated with endogenous neurotrophic factors. Excitotoxicity and oxidative stress Preclinical work suggests modulation of glutamate-associated injury and oxidative damage. Inflammation Some experimental models show altered inflammatory signaling. The most accurate description is therefore: Cerebrolysin is a complex peptide preparation with multiple proposed neuroprotective and neurotrophic mechanisms rather than a single-target drug.
What Does the Research Show?
Human research
This is where Cerebrolysin stands apart from Semax, Selank, DSIP and many other neuropeptides. There are randomized trials, multicenter trials, meta-analyses, and systematic reviews across several neurological indications. The evidence isn't absent. It's mixed. That's an important distinction. Some individual stroke and dementia studies report meaningful benefits. Other trials fail to demonstrate important differences. Systematic reviewers have repeatedly raised concerns involving trial size, risk of bias, heterogeneity, selective reporting, geographic concentration, and uncertain effects on hard clinical outcomes. So Cerebrolysin should be classified considerably above purely preclinical compounds—but below treatments supported by large, consistently positive modern clinical programs.
Animal research
Animal evidence is extensive. Models include ischemic stroke, traumatic brain injury, Alzheimer's pathology, neurodegeneration, aging, and spinal injury. Reported effects include reduced neuronal death, increased neurogenesis, improved behavioral recovery, increased synaptic plasticity, and reduced pathological signaling.
In-vitro research
Cell experiments have examined neuronal survival, amyloid toxicity, tau-related biology, oxidative injury, neurotrophic pathways, and neural progenitor cells. The complexity of the mixture makes identification of a single active component difficult.
Notable Studies
Safety and Efficacy of Cerebrolysin in Early Post-Stroke Recovery: A Meta-Analysis of Nine Randomized Clinical Trials
humanResearchers pooled randomized trials investigating Cerebrolysin during early recovery following ischemic stroke. The analysis reported favorable neurological and functional signals, particularly among more severely affected patients.
Limitations: Meta-analyses inherit limitations of included trials, including heterogeneity, relatively small individual studies, differing outcome measures and potential publication bias.
View publication →Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial
humanPatients received Cerebrolysin or placebo alongside a standardized rehabilitation program following acute ischemic stroke. Cerebrolysin was associated with greater improvement in upper-extremity motor function on the Action Research Arm Test.
Limitations: Relatively modest trial size, selected rehabilitation setting, and questions about generalizability. Results require consideration alongside less-positive trials and systematic reviews.
View publication →Cerebrolysin for Acute Ischaemic Stroke
humanCochrane reviewers evaluated randomized trials of Cerebrolysin added to standard therapy after acute ischemic stroke. The review did not find convincing evidence that Cerebrolysin reduces death or provides clear overall clinical benefit and raised concerns regarding adverse-event and trial-quality evidence.
Limitations: Available trials themselves were heterogeneous and often limited, meaning uncertainty works in both directions: the review cannot prove absence of every possible benefit, but the evidence does not establish one confidently.
View publication →What We Still Don't Know
- Which neurological indications genuinely benefit - Optimal treatment timing - Which stroke populations might respond - Whether motor-rehabilitation findings replicate broadly - Whether effects are clinically meaningful long term - Whether it modifies neurodegenerative disease progression - Which peptide components are biologically active - Exact molecular targets - Long-term safety across repeated treatment courses - Whether biomarker responses predict clinical outcomes - Why some trials are positive while others are neutral - Whether apparent benefits vary by rehabilitation intensity - Whether commercially sourced research material is equivalent to the standardized pharmaceutical product studied clinically
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Cerebrolysin research with you.
Get the Aminodex Cerebrolysin Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.